Articles published by Incyte
![](https://mms.businesswire.com/media/20240821420609/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240815184197/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240813897202/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240807597284/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240730670721/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240709787662/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Report Second Quarter Financial Results
July 09, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240708590802/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240607833063/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240530903016/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240521531442/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240521754461/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240514560354/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240502751076/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240430048388/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240411369652/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Report First Quarter Financial Results
April 11, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240401280916/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240329198758/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240310275231/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240304329736/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240229692531/en/2050221/5/TUJ_VOMPN_Logo_Primary.jpg)
![](https://mms.businesswire.com/media/20240227083647/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240215941438/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240213408157/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240205431773/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240123747153/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20240108325409/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231212377485/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231102793527/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
November 02, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231031837147/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 31, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231027752504/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
October 27, 2023
From Incyte
Via Business Wire
Tickers
INCY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.